We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Testosterone Replacement Therapy Decreases Plasma Paraoxonase 1 Enzyme Activity In Male Patients With Hypogonadism

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01107067
First Posted: April 20, 2010
Last Update Posted: April 20, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Gulhane School of Medicine
April 19, 2010
April 20, 2010
April 20, 2010
June 2008
December 2009   (Final data collection date for primary outcome measure)
paraoxonase level after testosterone treatment
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Testosterone Replacement Therapy Decreases Plasma Paraoxonase 1 Enzyme Activity In Male Patients With Hypogonadism
Phase IV Study to Investigate the Effect of Testosterone Treatment on Paraoxonase Level in Male Patients With Hypogonadotrophic Hypogonadism
The purpose of this study is investigating the effect of testosterone treatment on paraoxonase level in male patients with hypogonadotrophic hypogonadism
Not Provided
Interventional
Phase 4
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Screening
Hypogonadism
Drug: Sustanon
250 mg/21 days
Other Name: no name
Experimental: testosterone replacement therapy
Intervention: Drug: Sustanon
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
32
December 2009
December 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Volunteers patients with hypogonadism

Exclusion Criteria:

  • Coronary heart disease
  • Other pituitary/hypothalamic disorders or other non-hypogonadism diseases
  • None was receiving vitamins, lipid-lowering drugs, or other medications known to interfere with PON1 activity, lipid profile, or gonadal function
Sexes Eligible for Study: Male
20 Years to 25 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
Turkey
 
 
NCT01107067
aa001
No
Not Provided
Not Provided
Gulhane School of Medicine Department of Endocrinology and Metabolism
Gulhane School of Medicine
Not Provided
Not Provided
Gulhane School of Medicine
May 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP